Role of Glycation and Inflammation in Acute Ischemic Heart Disease

Action of Glycation and Inflammation in Operative Ischemic Heart Disease

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05112731

Acronym

AGLIANICO

Enrollment

Registered

2021-11-09

Start date

2022-02-01

Completion date

2023-12-31

Last updated

2024-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glycation End Products, Advanced, Heart Inflammation, Heart Injuries, Inflammation, Myocardial Infarction

Keywords

AGEs, BAFF, Myocardial Infarction

Brief summary

This study requires the consecutive enrollment of 60 patients following the first event of acute myocardial infarction, evaluating B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting (pre-reperfusion) and 3 months after reperfusion.

Detailed description

This study requires the consecutive enrollment of 60 patients at admission for first acute myocardial infarction. At enrollment, before reperfusion, a blood sample is obtained to measure B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting. This measure is then repeated at follow-up visit 3 months after reperfusion. The aim of the study is to identify specific subsets of patients and evaluate biomarkers variations.

Interventions

DIAGNOSTIC_TESTBAFF and MGO

measurement of BAFF and MGO levels before reperfusion and after 3 months

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* hospitalization for first myocardial infarction (STEMI or NSTEMI) * age between 18 and 80

Exclusion criteria

* uncompensated T2DM (HbA1c \>53mmol/mol) * use of anti-CD20 treatment * chronic anti-inflammatory treatment for autoimmune disease (i.e. DMARDs, high dose FANS, cortisonic drugs)

Design outcomes

Primary

Measure	Time frame	Description
Identification of Inflammatory Biomarkers (BAFF) linked to ischemic event and outcome	Day 0	elevation of BAFF levels
Identification of Glycation Biomarkers (MGO) linked to ischemic event and outcome	Day 0	elevation of MGO levels

Secondary

Measure	Time frame	Description
Identification of biomarkers variations (BAFF) complications and outcome	After 3 months	variation of BAFF from baseline
Identification of biomarkers variations (MGO) complications and outcome	After 3 months	variation of MGO from baseline

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026